Guess What Else is NOT a Top Priority of the FDA?

by Nolan and Auerbach on July 12, 2006

Answer: Monitoring postmarketing study commitments.

The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.

Leave a Comment

Disclaimer

Pharma 101 Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Pharma 101 Blog does not create an attorney-client relationship. Pharma 101 is the blog of Nolan & Auerbach, P.A. and it is intended primarily for other attorneys and regulatory professionals. No part of Pharma 101 Blog --whether information, commentary, or other-- may be attributed to Nolan & Auerbach, P.A.’s clients. Readers should be aware that Nolan & Auerbach, P.A. represents whistleblowers in the drug, medical device, and health care industries, and therefore Pharma 101 Blog may occasionally report on news that relates to Nolan & Auerbach, P.A. clients. Pharma 101 Blog will always strive to be unbiased in its reporting. All information on Pharma 101 Blog should be double-checked for its accuracy and current applicability.

Copyright 2009 Nolan & Auerbach, P.A.
Recent Posts
Links
- What Is Qui Tam?
Search Pharma 101